Biomarkers of Homeopathy in Fibromyalgia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00065702 |
Recruitment Status :
Completed
First Posted : August 1, 2003
Last Update Posted : August 18, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fibromyalgia | Drug: Active liquid remedy | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Study Start Date : | October 2000 |
Study Completion Date : | September 2002 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- ACR diagnosis of fibromyalgia;
- Willing to take daily active or placebo liquid remedy under double blind conditions for 6 months, involving daily succussion and dilution of source liquid from a stock bottle;
- Willingness/ability to comply with dietary and lifestyle restrictions, i.e., no coffee in any form, no comphor or menthol-containing products; no electric blankets, no strong aromatics, no routine vaccinations, no concomitant use of acupuncture, chiropractic, polarity therapy, psychic healing, or magnet therapy;
- No dental drilling, MRI scans unless emergent;
- Withhold food or drink 30 mins before/after therapy;
- Stable conventional care for 2 months prior to entry;
- Willing to undergo 3 diagnostic physical exams, and to permit videotaping of interview sessions;
- Willing to fill out questionnaires
Exclusion criteria:
- Steroid-dependent medical conditions;
- Chronic benzodiazepine or anticonvulsant use;
- Use of tricyclic antidepressants, antihypertensives, and other drugs that alter orthostasis;
- Pregnancy;
- History of seizure disorder or syncope;
- Life-threatening medical conditions;
- Current active asthma;
- History of anaphylactic shock;
- Insulin-dependent diabetes;
- Active suicidal ideation or psychosis.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00065702
United States, Arizona | |
U of Arizona College of Medicine, Program in Integrative Medicine | |
Tucson, Arizona, United States, 85724 |
Principal Investigator: | Iris R. Bell, MD, PhD | University of Arizona College of Medicine |
ClinicalTrials.gov Identifier: | NCT00065702 |
Other Study ID Numbers: |
R21AT000315-01 ( U.S. NIH Grant/Contract ) BellI |
First Posted: | August 1, 2003 Key Record Dates |
Last Update Posted: | August 18, 2006 |
Last Verified: | August 2006 |
fibromyalgia homeopathy EEG EKG chronic pain |
Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases |
Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases |